KTTA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pasithea Therapeutics Corp (KTTA) is not a good buy for a long-term beginner investor at this time. The technical indicators are bearish, there are no positive trading signals, and the financial performance is weak with declining EPS and negative net income. Additionally, there are no significant catalysts or news to suggest a strong upward trend in the near future.
The MACD is negative and contracting, RSI is neutral at 40.766, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 0.81, with key support at 0.761 and resistance at 0.859. Overall, the technical indicators suggest a bearish trend.
NULL identified. No recent news or significant trading trends to act as a positive catalyst.
Weak financial performance with negative net income and declining EPS. Bearish technical indicators and no significant trading trends from hedge funds or insiders.
In Q3 2025, revenue remained at 0 with no growth YoY. Net income was -$3,037,420, a slight improvement of 1.25% YoY, but EPS dropped significantly by -85.71% YoY to -0.41. Gross margin remained at 0 with no growth. Overall, the financials indicate poor performance.
No analyst rating or price target changes available.
